Reducing Alzheimer’s Disease Burden Through Early Diagnosis and Treatment

Key opinion leaders discuss the clinical burden for a patient with Alzheimer disease and enumerate available drug and nondrug treatment options.

A discussion on the various unmet needs in the treatment of Alzheimer disease.

Panelists consider at what point in the disease development patients typically access the health care system for diagnosis and treatment.

Experts in the management of Alzheimer disease consider the increased prevalence of Alzheimer disease in the United States with growing geriatric populations and how the health care system is adapting.

A discussion on the disparity in access to quality health care between various patient populations.

Key opinion leaders discuss which factors contribute to patients and caregivers deciding to seek health care guidance and assistance for Alzheimer disease.

A discussion on the typical journey of a patient with Alzheimer disease from initial presentation to proper diagnosis within the health care system.

Experts in the management of Alzheimer disease consider the future goals of therapy in tandem with the development of early detection polices.

Expert panelists discuss methods to better monitor comorbidities and adverse effects associated with Alzheimer disease.

Key opinion leaders consider effective ways to improve access to appropriate care for individuals with Alzheimer disease.

Panelists discuss how to craft future policies for early biomarker detection to use developing therapies that target underlying pathophysiology.

A discussion on the stratification of patient populations for treatment eligibility based on various decision factors.

Key opinion leaders discuss possible ways to mitigate the increased cost of Alzheimer disease treatment.

A member of the American Brain Foundation discusses the organization’s role in the development of Alzheimer disease management and improvement in education.

Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response.

Panelists conclude the discussion with personal insight into the promising future of Alzheimer disease treatment.